2001 TJP Prozac

2001 TJP Prozac

In collections

Dyck

Metadata (MODS)
Titles	2001 TJP Prozac
Related Item
Genre	medicine
Identifier	TJP199
Note	Prozac 20mg Dispersible. New Prozac 20mh dispersible tablet for greater patients confidence. Depressed patients with anxiety: "Although the initial 20 mg/day starting dose for fluoxetine is the full therapeutic does in most patients, the fluoxetine dose for patients with symptoms of anxiety should often be titrated. Elderly Depression: Clinical studies show no necessity for reducing fluoxetine dose for the elderly. "……studies of fluoxetine in older individuals showed no significant differences from younger volunteers in clearance of a single dose of drug." New Prozac dispersible tablet for: Improved Patient Compliance: If adverse events are experience, these may be dose related and a lower does should be considered to help manage side effects. New Prozac 20mg dispersible tablet for: Individual dosing convenience: Although 20mg/day floxetine is the recommended therapeutic dose, the new formulation offers convenience of tailoring a dose to specific patient needs. Prozac 20 Dispersible Tablet (fluoxetine hydrochloride, Lilly) A) INN/USAN Name and Pharmacotherapeutic Group: Fluoxetine (INN)/Fluoxetine hydrochloride (USAN) is a selective serotonin reuptake inhibitor. B) Pharmaceutical Form: Fluoxetine is supplied as a dispersible tablet containing fluoxetine hydrochloride equivalent to 2 mg fluoxetine. Therapeutic Indications: Depression or depression with or without associated anxiety, Obsessive compulsive disorder. C.3) Contraindications Hypersensitivity: Fluoxetine is contraindicated in patients know to be hypersensitive to it. MAO1AL Fluoxetine should not be used in combination with a monoamine oxidase (MAOI), Fluoxetine should not be used within a minimum of 14 days of discontinuing therapy with an MAOI, At least 5 weeks should elapse between discontinuation of fluoxetine and initiation of therapy with an MAOI. If weeks should elapse between discontinuation of fluoxetine and initation of therapy with an MAOI. If fluoxetine has been prescribed chronically and/or at a high dose, a longer interval should be considered. C.4) Special warning and special precautions for use: WARNINGS: Rash: Rash, anaphylactoid events and progressive systemic events, sometimes serious and involving skin, kidney, liver, or lung have been reported in patients taking fluoxetine. Upon the appearance of rash, or of other possible allergic phenomena for which an alternative aetiology cannot be identifies, fluoxetine should be discontinued. PRECAUTIONS: Seizures: As with other antidepressants, fluoxetine should be introduce cautiously in patients who have a history of seizures. Hyponatremia: Cases of hyponatremia (some with serum sodium lower than 110 mmol/L) have been reported. The majority of these cases occurred in elderly patients treated with diuretics or otherwise volume-depleted. Glycemic control: In patients with diabetes, hypoglycaemia has occurred during therapy and hyperglycemia has developed following discontinuation. Insulin and/or oral hypoglycan age may need to be adjusted when fluoxetine is initiated or discontinued. C.9) Overdose: Symptoms: Cases of overdose of fluoxetine alone usually have a mind course. Symptoms of mind have included nausea, vomiting, seizures, and signs of CNS excitation.
Abstract	Fluoxetine hydrochroride, Eli Lilly Asia, Inc. Image of glass of water (half filled) and it is opaque, so assuming a tablet has dispersed into it. Behind is there is a box and a pack of tablets, with one tablet missing from the pack.